Data Insights

Tipifarnib by Kura Oncology for Recurrent Head And Neck Squamous Cell Carcinoma: Likelihood of Approval

Tipifarnib is under clinical development by Kura Oncology and currently in Phase II for Recurrent Head And Neck Squamous Cell...

Likelihood of Approval and Phase Transition Success Rate Model - Tipifarnib in Recurrent Head And Neck Squamous Cell Carcinoma

Data Insights

Tipifarnib by Kura Oncology for Head And Neck Squamous Cell Carcinoma (HNSC): Likelihood of Approval

Tipifarnib is under clinical development by Kura Oncology and currently in Phase II for Head And Neck Squamous Cell Carcinoma...

Likelihood of Approval and Phase Transition Success Rate Model - Tipifarnib in Head And Neck Squamous Cell Carcinoma (HNSC)

Data Insights

Ziftomenib by Kura Oncology for Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia): Likelihood of Approval

Ziftomenib is under clinical development by Kura Oncology and currently in Phase II for Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic...

Likelihood of Approval and Phase Transition Success Rate Model - Ziftomenib in Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia)

Data Insights

KO-2806 by Kura Oncology for Pancreatic Ductal Adenocarcinoma: Likelihood of Approval

KO-2806 is under clinical development by Kura Oncology and currently in Phase I for Pancreatic Ductal Adenocarcinoma. According to GlobalData,...

Likelihood of Approval and Phase Transition Success Rate Model - KO-2806 in Pancreatic Ductal Adenocarcinoma

Data Insights

Ziftomenib by Kura Oncology for Relapsed Acute Myeloid Leukemia: Likelihood of Approval

Ziftomenib is under clinical development by Kura Oncology and currently in Phase II for Relapsed Acute Myeloid Leukemia. According to...

Likelihood of Approval and Phase Transition Success Rate Model - Ziftomenib in Relapsed Acute Myeloid Leukemia

Data Insights

Ziftomenib by Kura Oncology for Refractory Acute Myeloid Leukemia: Likelihood of Approval

Ziftomenib is under clinical development by Kura Oncology and currently in Phase II for Refractory Acute Myeloid Leukemia. According to...

Likelihood of Approval and Phase Transition Success Rate Model - Ziftomenib in Refractory Acute Myeloid Leukemia